Primary Progressive Aphasia Overview

Save information for later
Sign Up

Learn About Primary Progressive Aphasia

What is the definition of Primary Progressive Aphasia?
Primary progressive aphasia (PPA) affects a person's ability to use language to communicate. This includes loss of ability to understand or express speech (aphasia). PPA is a specific type of a more general disease called frontotemporal dementia. PPA can be classified into three distinct types: progressive non-fluent aphasia (PNFA), semantic dementia (SD), and logopenic progressive aphasia (LPA). PPA is caused by a loss of tissue (atrophy) in the area of the brain that is responsible for producing language. In some cases, this loss of tissue is caused by genetic changes (genetic changes or pathogenic variants) in the GRN gene. In these cases, the disease is inherited in an autosomal dominant manner. Diagnosis of PPA is suspected when a doctor observes signs and symptoms such as progressive loss of language abilities. Imaging of the brain can confirm the diagnosis.
What are the alternative names for Primary Progressive Aphasia?
  • Primary progressive aphasia
  • Aphasia, primary progressive
  • PPA
  • Primary progressive aphasia syndrome
Who are the top Primary Progressive Aphasia Local Doctors?
Distinguished in Primary Progressive Aphasia
Dr. Kyan Younes
Neurology | Psychiatry
Distinguished in Primary Progressive Aphasia
Dr. Kyan Younes
Neurology | Psychiatry

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (4.7 mi)
650-723-4000
Languages Spoken:
English
Offers Telehealth

Kyan Younes is a Neurologist and a Psychiatrist in Stanford, California. Dr. Younes and is rated as a Distinguished provider by MediFind in the treatment of Primary Progressive Aphasia. His top areas of expertise are Frontotemporal Dementia, Primary Progressive Aphasia, Cerebellar Degeneration, Dementia, and Thrombectomy.

Advanced in Primary Progressive Aphasia
Dr. Sharon J. Sha
Psychiatry | Neurology
Advanced in Primary Progressive Aphasia
Dr. Sharon J. Sha
Psychiatry | Neurology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (4.7 mi)
650-723-4000
Languages Spoken:
English
Offers Telehealth

Sharon Sha is a Psychiatrist and a Neurologist in Stanford, California. Dr. Sha and is rated as an Advanced provider by MediFind in the treatment of Primary Progressive Aphasia. Her top areas of expertise are Alzheimer's Disease, Lewy Body Dementia (LBD), Memory Loss, and Dementia.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Primary Progressive Aphasia
Dr. Edmond H. Teng
Neurology | Psychiatry
Advanced in Primary Progressive Aphasia
Dr. Edmond H. Teng
Neurology | Psychiatry

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (4.7 mi)
650-723-4000
Languages Spoken:
English

Edmond Teng is a Neurologist and a Psychiatrist in Stanford, California. Dr. Teng and is rated as an Advanced provider by MediFind in the treatment of Primary Progressive Aphasia. His top areas of expertise are Alzheimer's Disease, Dementia, Developmental Dysphasia Familial, and Memory Loss.

View All Doctors
What are the latest Primary Progressive Aphasia Clinical Trials?
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Enrollment Status: Recruiting
Publish Date: February 21, 2025

Background: Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors.

Match to trials
Find the right clinical trials for you in under a minute
Get started
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Enrollment Status: Recruiting
Publish Date: February 13, 2025

Summary: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center